Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02887859 · ClinicalTrials.gov registry record · Phase 2
Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD
A Phase 2 study of Peripheral Artery Disease, sponsored by Humacyte.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 5
- Study locations
NCT02887859: Completed Phase 2 study of Peripheral Artery Disease, sponsored by Humacyte.
NCT02887859 is a Phase 2 study of Peripheral Artery Disease that has completed, run by Humacyte. The registered enrollment target is 15 participants, below the 126-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (88% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02887859, a Phase 2 study of Peripheral Artery Disease, has completed, sponsored by Humacyte.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study will evaluate how well Humacyte's Human Acellular Vessel (HAV) works when surgically implanted into a leg to improve blood flow in patients with peripheral arterial disease (PAD). This study will also evaluate how safe it is to use the HAV in this manner.
Conditions Studied
Interventions
- BIOLOGICAL Human Acellular Vessel (HAV)
Study Locations (5)
California
- UCSF - San Francisco
Massachusetts
- Brigham and Women's Hospital - Boston
Michigan
- Michigan Vascular Center - Flint
New Jersey
- Overlook Medical Center - Summit
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2016-12-20 |
| Est. Completion | 2023-12 |
| Phase | Phase 2 |
What the finished NCT02887859 record still lists
NCT02887859 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 126-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Peripheral Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which Human Acellular Vessel (HAV) is the first listed.
NCT02887859 lists 5 locations in 5 states (California, Massachusetts, Michigan).
Frequently Asked Questions
What is clinical trial NCT02887859 about?
NCT02887859 is a clinical study titled "Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD". This study will evaluate how well Humacyte's Human Acellular Vessel (HAV) works when surgically implanted into a leg to improve blood flow in patients with peripheral arterial disease (PAD). This study will also evaluate how safe it is to use the HAV in this manner.
What is the current status of trial NCT02887859?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2016-12-20. Estimated completion is 2023-12.
What conditions does trial NCT02887859 study?
This clinical trial studies the following conditions: Peripheral Artery Disease.
What interventions are being tested in trial NCT02887859?
The interventions under investigation include: Human Acellular Vessel (HAV) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02887859?
This trial is sponsored by Humacyte, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02887859 being conducted?
This trial has 5 study locations across California, Massachusetts, Michigan, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02887859's enrollment target sits among peer trials
15 44th of 50 higher than 7 of 50 other Peripheral Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Response to Exercise and Nitric Oxide in PAD
RECRUITING · Phase 2
-
Dysvascular Amputation Self-Management of Health
COMPLETED · Phase 2
-
The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication
RECRUITING · Phase 1
-
Improving Mobility After Revascularization in Peripheral Artery Disease
RECRUITING · Phase 3
-
The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease
RECRUITING · NA
-
BEETroot Juice to Reverse Functional Impairment in PAD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI